Business travelers: Vaccination considerations for this population

Expert Review of Vaccines

Volumn 12, Issue 4, 2013, Pages 453-466

  Chen, Lin H ^a,d   Leder, Karin ^b   Wilson, Mary E ^c  

^a MOUNT AUBURN HOSPITAL   (United States)

^b MONASH UNIVERSITY   (Australia)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

business expatriate; business traveler; corporate travel; multinational corporation; pretravel advice; vaccination

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; JAPANESE ENCEPHALITIS VACCINE; MENINGOCOCCUS VACCINE; TYPHOID VACCINE;

AFRICA; ALCOHOL CONSUMPTION; BITE; BUSINESS TRAVELER; CHEMOPROPHYLAXIS; CHOLERA; DIARRHEA; FATIGUE; HEALTH CARE COST; HEALTH INSURANCE; HEPATITIS A; HEPATITIS B; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INFLUENZA; JAPANESE ENCEPHALITIS; MALARIA; MEDICAL ASSESSMENT; MENINGOCOCCOSIS; MENTAL STRESS; NAMED GROUPS BY OCCUPATION; OCCUPATIONAL ACCIDENT; POLIOMYELITIS; PREGNANT WOMAN; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PRODUCTIVITY; RABIES; RESPIRATORY TRACT DISEASE; REVIEW; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; TICK BORNE ENCEPHALITIS; TRAVEL; TYPHOID FEVER; UNITED STATES; VACCINATION; YELLOW FEVER;

COMMERCE; COMMUNICABLE DISEASES; HUMANS; RISK ASSESSMENT; TOPOGRAPHY, MEDICAL; TRAVEL; TRAVEL MEDICINE; VACCINATION;

EID: 84875926007     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.16     Document Type: Review

References (88)

1. Hamer DH, MacLeod WB, Chen LH et al. Demographic characteristics and trip plans of a cohort of travelers seen at the Boston area travel medicine network. Presented at: 11th Conference of the International Society of Travel Medicine (ISTM), Budapest, Hungary, 24-28 May 2009.
2. LaRocque RC, Rao SR, Lee J et al.; Global TravEpiNet Consortium. Global TravEpiNet: a national consortium of clinics providing care to international travelers-analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin. Infect. Dis. 54(4), 455-462 (2012).
3. Van Herck K, Zuckerman J, Castelli F, Van Damme P, Walker E, Steffen R; European Travel Health Advisory Board. Travelers' knowledge, attitudes, and practices on prevention of infectious diseases: results from a pilot study. J. Travel Med. 10(2), 75-78 (2003).
4. Patel D, Easmon C, Seed P, Dow C, Snashall D. Morbidity in expatriates -a prospective cohort study. Occup. Med. (Lond.) 56(5), 345-352 (2006). (Pubitemid 44304827)
5. Easmon C. Health and safety aspects of business travel. J. R. Soc. Promot. Health 122(1), 7-8 (2002). (Pubitemid 34406588)
6. Burkholder JD, Joines R, Cunningham-Hill M, Xu B. Health and well-being factors associated with international business travel. J. Travel Med. 17(5), 329-333 (2010).
7. Chen LH, Wilson ME, Davis X et al.; GeoSentinel Surveillance Network. Illness in long-term travelers visiting GeoSentinel clinics. Emerging Infect. Dis. 15(11), 1773-1782 (2009).
8. Leder K, Chen LH, Wilson ME. Aggregate travel vs. single trip assessment: arguments for cumulative risk analysis. Vaccine 30(15), 2600-2604 (2012).
9. Hudson TW, Fortuna J. Overview of selected infectious disease risks for the corporate traveler. J. Occup. Environ. Med. 50(8), 924-934 (2008).
10. Weber R, Schlagenhauf P, Amsler L, Steffen R. Knowledge, attitudes and practices of business travelers regarding malaria risk and prevention. J. Travel Med. 10(4), 219-224 (2003). (Pubitemid 36987925)
11. Berg J, Breederveld D, Roukens AH et al. Knowledge, attitudes, and practices toward malaria risk and prevention among frequent business travelers of a major oil and gas company. J. Travel Med. 18(6), 395-401 (2011).
12. Aro AR, Vartti AM, Schreck M, Turtiainen P, Uutela A. Willingness to take travelrelated health risks-a study among Finnish tourists in Asia during the avian influenza outbreak. Int. J. Behav. Med. 16(1), 68-73 (2009).
13. Connor BA, Patron DJ. Use of an accelerated immunization schedule for combined hepatitis A and B protection in the corporate traveler. J. Occup. Environ. Med. 50(8), 945-950 (2008).
14. Van Herck K, Van Damme P, Castelli F et al. Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J. Travel Med. 11(1), 3-8 (2004). (Pubitemid 38198768)
15. Liese B, Mundt KA, Dell LD, Nagy L, Demure B. Medical insurance claims associated with international business travel. Occup. Environ. Med. 54(7), 499-503 (1997). (Pubitemid 27308482)
16. Bunn W. Vaccine and international health programs for employees traveling and living abroad. J. Travel Med. 8(Suppl. 1), S20-S23 (2001). (Pubitemid 32231579)
17. Bunn WB. Risk and burden associated with the acquisition of viral hepatitis A and B in the corporate traveler. J. Occup. Environ. Med. 50(8), 935-944 (2008).
18. Kemmerer TP, Cetron M, Harper L, Kozarsky PE. Health problems of corporate travelers: risk factors and management. J. Travel Med. 5(4), 184-187 (1998). (Pubitemid 28562326)
19. Wilson ME, Weld LH, Boggild A et al.; GeoSentinel Surveillance Network. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin. Infect. Dis. 44(12), 1560-1568 (2007). (Pubitemid 46871502)
20. Leder K, Black J, O'Brien D et al. Malaria in travelers: a review of the GeoSentinel surveillance network. Clin. Infect. Dis. 39(8), 1104-1112 (2004). (Pubitemid 40169306)
21. Leder K, Sundararajan V, Weld L, Pandey P, Brown G, Torresi J; GeoSentinel Surveillance Groupa. Respiratory tract infections in travelers: a review of the GeoSentinel surveillance network. Clin. Infect. Dis. 36(4), 399-406 (2003). (Pubitemid 36241304)
22. Boggild AK, Castelli F, Gautret P et al.; GeoSentinel Surveillance Network. Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine 28(46), 7389-7395 (2010).
23. Ward BJ, Plourde P. Travel and sexually transmitted infections. J. Travel Med. 13(5), 300-317 (2006). (Pubitemid 44434294)
24. Carter S, Horn K, Hart G, Dunbar M, Scoular A, MacIntyre S. The sexual behaviour of international travellers at two Glasgow GUM clinics. Glasgow genitourinary medicine. Int. J. STD AIDS 8(5), 336-338 (1997). (Pubitemid 27202421)
25. Steffen R, Rickenbach M, Wilhelm U, Helminger A, Schär M. Health problems after travel to developing countries. J. Infect. Dis. 156(1), 84-91 (1987). (Pubitemid 17089388)
26. Richards CA, Rundle AG. Business travel and self-rated health, obesity, and cardiovascular disease risk factors. J. Occup. Environ. Med. 53(4), 358-363 (2011).
27. Striker J, Luippold RS, Nagy L, Liese B, Bigelow C, Mundt KA. Risk factors for psychological stress among international business travellers. Occup. Environ. Med. 56(4), 245-252 (1999). (Pubitemid 29129236)
28. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 61(40), 816-819 (2012).
29. Chen LH, Wilson ME. The role of the traveler in emerging infections and magnitude of travel. Med. Clin. North Am. 92(6), 1409-1432, xi (2008).
30. CDC. Measles -United States, 2011. MMWR Morb. Mortal Wkly. Rep. 61, 253-257 (2012).
31. Mulholland EK, Griffiths UK, Biellik R. Measles in the 21st century. N. Engl. J. Med. 366(19), 1755-1757 (2012).
32. CDC. Updated recommendations for use of meningococcal conjugate vaccines -Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal Wkly. Rep. 60(3), 72-76 (2011).
33. Külshammer M, Winke U, Frank M et al. Poor immunity status against poliomyelitis in medical students: a semi-anonymous study. Med. Microbiol. Immunol. 202(1), 63-65 (2012).
34. Baldo V, Baldovin T, Cocchio S et al. Seroepidemiology of polioviruses among university students in northern Italy. Clin. Vaccine Immunol. 19(8), 1292-1295 (2012).
35. Helfenberger S, Tschopp A, Robyn L, Hatz C, Schlagenhauf P. Knowledge, attitudes, and practices of business travelers regarding influenza and the use of antiviral medication. J. Travel Med. 17(6), 367-373 (2010).
36. Nielsen US, Petersen E, Larsen CS. Hepatitis B immunization coverage and risk behaviour among Danish travellers: are immunization strategies based on single journey itineraries rational? J. Infect. 59(5), 353-359 (2009).
37. McMahon BJ, Dentinger CM, Bruden D et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J. Infect. Dis. 200(9), 1390-1396 (2009).
38. Connor BA, Blatter MM, Beran J, Zou B, Trofa AF. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J. Travel Med. 14(1), 9-15 (2007). (Pubitemid 46114981)
39. van Genderen PJ, van Thiel PP, Mulder PG, Overbosch D; Dutch Schiphol Airport Study Group. Trends in knowledge, attitudes, and practices of travel risk groups toward prevention of hepatitis A: results from the Dutch Schiphol Airport survey to 2009. J. Travel Med. 19(1), 35-43 (2012).
40. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. J. Infect. Dis. 171(Suppl. 1), S44-S49 (1995).
41. Victor JC, Monto AS, Surdina TY et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N. Engl. J. Med. 357(17), 1685-1694 (2007). (Pubitemid 350005150)
42. Thoelen S, Van Damme P, Leentvaar-Kuypers A et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 17(13-14), 1657-1662 (1999). (Pubitemid 29138897)
43. Kallinowski B, Knoll A, Lindner E et al. Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course? Vaccine 19, 16-22 (2001). (Pubitemid 30618950)
44. CDC. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59(RR-1), 1-27 (2010).
45. Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am. J. Trop. Med. Hyg. 82(5), 930-936 (2010).
46. CDC. Japanese encephalitis in two children -United States, 2010. MMWR Morb. Mortal Wkly. Rep. 60(9), 276-278 (2011).
47. Dubischar-Kastner K, Eder S, Buerger V et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 28(32), 5197-5202 (2010).
48. Woolpert T, Staples JE, Faix DJ et al. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine 30(20), 3090-3096 (2012).
49. Erra EO, Askling HH, Yoksan S et al. Cross-protective capacity of japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin. Infect. Dis. 56(2), 267-270 (2013).
50. Nasveld PE, Ebringer A, Elmes N et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year Phase II study in healthy adults. Hum. Vaccin. 6(12), 1038-1046 (2010).
51. Gautret P, Schwartz E, Shaw M et al.; GeoSentinel Surveillance Network. Animal-associated injuries and related diseases among returned travellers: a review of the GeoSentinel Surveillance Network. Vaccine 25(14), 2656-2663 (2007). (Pubitemid 46400926)
52. Wijaya L, Ford L, Lalloo D. Rabies postexposure prophylaxis in a UK travel clinic: ten years' experience. J. Travel Med. 18(4), 257-261 (2011).
53. Uwanyiligira M, Landry P, Genton B, de Valliere S. Rabies postexposure prophylaxis in routine practice in view of the new Centers for Disease Control and Prevention and World Health Organization recommendations. Clin. Infect. Dis. 55(2), 201-205 (2012).
54. Gautret P, Parola P. Rabies vaccination for international travelers. Vaccine 30(2), 126-133 (2012).
55. Ross RS, Wolters B, Viazov SO, Roggendorf M. Awareness of rabies risks and knowledge about preventive measures among experienced German travel health advisors. J. Travel Med. 13(5), 261-267 (2006). (Pubitemid 44434288)
56. Ochiai RL, Acosta CJ, Danovaro-Holliday MC et al.; Domi Typhoid Study Group. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull. World Health Organ. 86(4), 260-268 (2008). (Pubitemid 351521852)
57. Lynch MF, Blanton EM, Bulens S et al. Typhoid fever in the United States, 1999-2006. JAMA 302(8), 859-865 (2009).
58. Kendall ME, Crim S, Fullerton K et al. Travel-associated enteric infections diagnosed after return to the United States, Foodborne Diseases Active Surveillance Network (FoodNet), 2004-2009. Clin. Infect. Dis. 54(Suppl. 5), S480-S487 (2012).
59. Patel TA, Armstrong M, Morris-Jones SD, Wright SG, Doherty T. Imported enteric fever: case series from the hospital for tropical diseases, London, United Kingdom. Am. J. Trop. Med. Hyg. 82(6), 1121-1126 (2010).
60. Johnson KJ, Gallagher NM, Mintz ED, Newton AE, Brunette GW, Kozarsky PE. From the CDC: new country-specific recommendations for pre-travel typhoid vaccination. J. Travel Med. 18(6), 430-433 (2011).
61. Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 316(7125), 110-116 (1998). (Pubitemid 28121109)
62. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J. Infect. Dis. 159(4), 766-769 (1989). (Pubitemid 19105635)
63. WHO. Yellow fever in Africa and Central and South America, 2008-2009. Wkly. Epidemiol. Rec. 86(4), 25-36 (2011).
64. Jentes ES, Poumerol G, Gershman MD et al.; Informal WHO Working Group on Geographic Risk for Yellow Fever. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect. Dis. 11(8), 622-632 (2011).
65. Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Vaccines (5th Edition). Plotkin SA, Orenstien WA, Offit PA (Eds). Saunders, PA, USA, 959-1055 (2008).
66. Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev. Vaccines 11(4), 427-448 (2012).
67. Staples JE, Gershman M, Fischer M; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recomm. Rep. 59(RR-7), 1-27 (2010).
68. Barwick Eidex R; Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination. Lancet 364(9438), 936 (2004).
69. Lindsey NP, Schroeder BA, Miller ER et al. Adverse event reports following yellow fever vaccination. Vaccine 26(48), 6077-6082 (2008).
70. Chen LH, Hill DR, Wilder-Smith A. Vaccination of travelers: how far have we come and where are we going? Expert Rev. Vaccines 10(11), 1609-1620 (2011).
71. WHO. International Health Regulations (2nd Edition). WHO, Geneva, Switzerland (2005).
72. WHO. Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol. Rec. 86(24), 241-256 (2011).
73. CDC. Tick-borne encephalitis among U.S. travelers to Europe and Asia -2000-2009. MMWR Morb. Mortal Wkly. Rep. 59(11), 335-338 (2010).
74. Demicheli V, Debalini MG, Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst. Rev. 1, CD000977 (2009).
75. Shin S, Desai SN, Sah BK, Clemens JD. Oral vaccines against cholera. Clin. Infect. Dis. 52(11), 1343-1349 (2011).
76. Hamer DH, Ruffing R, Callahan MV, Lyons SH, Abdullah AS. Knowledge and use of measures to reduce health risks by corporate expatriate employees in western Ghana. J. Travel Med. 15(4), 237-242 (2008). (Pubitemid 352020249)
77. Smalligan RD, Lange WR, Frame JD, Yarbough PO, Frankenfield DL, Hyams KC. The risk of viral hepatitis A, B, C, and E among North American missionaries. Am. J. Trop. Med. Hyg. 53(3), 233-236 (1995).
78. Menachem M, Grupper M, Paz A, Potasman I. Assessment of rabies exposure risk among Israeli travelers. Travel Med. Infect. Dis. 6(1-2), 12-16 (2008). (Pubitemid 351372737)
79. Nayyar GM, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect. Dis. 12(6), 488-496 (2012).
80. United Nations World Tourism Organisation. Tourism Highlights 2012 Edition. www2.unwto.org/en (Accessed 19 July 2012)
81. Office of Travel and Tourism Industries, US Department of Commerce. Profile of U.S. Resident Travelers Visiting Overseas Destinations: 2011 Outbound. http://tinet.ita.doc.gov/outreachpages/ download-data-table/2011- Outbound- Profile.pdf (Accessed 16 August 2012)
82. United Nations World Tourism Organisation. Understanding Tourism: Basic Glossary. http://media.unwto.org/en/content/ understanding-tourism-basic- glossary (Accessed 19 July 2012)
83. GeoSentinel Surveillance Network. www.istm.org/geosentinel/main.html (Accessed 20 July 2012)
84. Centers for Disease Control and Prevention. Areas with frequent epidemics of meningococcal meningitis. wwwnc.cdc.gov/travel/yellowbook/2012/ chapter-3-infectious-diseases-related-totravel/ meningococcal-disease.htm#2572 (Accessed 31 July 2012)
85. Global Polio Eradication Initiative. The current status of polio circulation. www.polioeradication.org/Dataandmonitoring. aspx (Accessed July 31 2012)
86. WHO. International Travel and Health. Geneva: World Health Organization Press. 2011. www.who.int/ith (Accessed 31 July 2012)
87. Centers for Disease Control and Prevention. Traveler's Health web site. wwwnc.cdc.gov/travel/default.aspx (Accessed 31 July 2012)
88. TBE distribution map. www.tbefacts.com/images/fig11-worldwide. gif (Accessed 25 August 2012)